# HS-IT101 Injection for Advanced NSCLC

> **NCT07105176** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qingdao Sino-Cell Biomedicine Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** IL-2 (interleukin 2)
- **DRUG:** HS-IT101 monotherapy

## Key facts

- **NCT ID:** NCT07105176
- **Lead sponsor:** Qingdao Sino-Cell Biomedicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105176, "HS-IT101 Injection for Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07105176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*